Skull Base Tumors: Neuropathology and Clinical Implications
- 24 November 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 90 (3) , 243-261
Abstract
Tumors that arise in and around the skull base comprise a wide range of common and rare entities. Recent studies have advanced our understanding of their pathogenesis, which in some cases, have significantly influenced clinical practice. The genotype of meningiomas is strongly associated with their phenotype, including histologic subtype and tumor location, and clinical outcome. A single molecular alteration, NAB2-STAT6 fusion, has redefined the category of solitary fibrous tumors to include the previous entity hemangiopericytomas. Schwannomas, both sporadic and familial, are characterized by near ubiquitous alterations in NF2, with additional mutations in SMARCB1 or LZTR1 in schwannomatosis. In pituitary adenohypophyseal tumors, cell lineage transcription factors such as SF-1, T-PIT, and PIT-1 are now essential for classification, providing a more rigorous taxonomy for tumors that were previously considered null cell adenomas. The pituicyte lineage transcription factor TTF-1 defines neurohypophyseal tumors, which may represent a single nosological entity with a spectrum of morphologic manifestations (ie, granular cell tumor, pituicytoma, and spindle cell oncocytoma). Likewise, the notochord cell lineage transcription factor brachyury defines chordoma, discriminating them from chondrosarcomas. The identification of nonoverlapping genetic drivers of adamantinomatous craniopharyngiomas and papillary craniopharyngiomas indicates that these are distinct tumor entities and has led to successful targeted treatment of papillary craniopharyngiomas using BRAF and/or mitogen–activated protein kinase inhibitors. Similarly, dramatic therapeutic responses have been achieved in patients with Langerhans cell histiocytosis, both with BRAF-mutant and BRAF-wildtype tumors. Familiarity with the pathology of skull base tumors, their natural history, and molecular features is essential for optimizing patient care.Keywords
This publication has 151 references indexed in Scilit:
- Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteriaAmerican Journal of Medical Genetics Part A, 2013
- Loss of SUFU Function in Familial Multiple MeningiomaThe American Journal of Human Genetics, 2012
- Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutationFamilial Cancer, 2012
- Incidence, Predictive Factors, and Prognosis of Chondrosarcoma in Patients with Ollier Disease and Maffucci Syndrome: An International Multicenter Study of 161 PatientsThe Oncologist, 2011
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Immunohistochemical Analysis Supports a Role for INI1/SMARCB1 in Hereditary Forms of Schwannomas, but Not in Solitary, Sporadic SchwannomasBrain Pathology, 2008
- Germline Mutation of INI1/SMARCB1 in Familial SchwannomatosisThe American Journal of Human Genetics, 2007
- Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngiomaThe Journal of Pathology, 2004
- Alterations of the Tumor Suppressor Genes CDKN2A (p16), p14, CDKN2B (p15), and CDKN2C (p18) in Atypical and Anaplastic MeningiomasThe American Journal of Pathology, 2001
- Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22Nature, 1987